Swissmedic
REGULATORY UPDATE
New strategic approach to minimizing animal testing in the development of medicinal products
Published: 10/19/2026Detected: 10/19/2026
Summary preview
Establishes a strategic approach intended to reduce the reliance on animal testing in the development of medicinal products, shifting expectations toward alternative methods and more science-based justification.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountmanufacturing
quality
clinical
safety
labeling
#animal testing
#nonclinical development
#3Rs
#alternative methods
#in vitro
Official Source Document Source Verified
Access the original document directly from SWISSMEDIC.
More from Swissmedic
- GMP compliance by foreign manufacturers10/9/2026
- Changes to the Guidance document “Import of a human medicinal product according to Art. 14 para. 2 and 3 TPA (parallel import)”10/1/2026
- Adaptations required for issuing establishment licences and GMP certificates for manufacturers of active substances10/1/2026
- Revision of the Guidance document Authorisation Biosimilar10/1/2026
- Swissmedic Portal Release – New Features Available from 23 September 20269/24/2026